239 related articles for article (PubMed ID: 35628480)
41. Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.
Peng J; Hasserjian RP; Tang G; Patel KP; Goswami M; Jabbour EJ; Garcia-Manero G; Medeiros LJ; Wang SA
Leuk Lymphoma; 2016; 57(4):812-9. PubMed ID: 26293512
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.
Tenti E; Papayannidis C; Marconi G; Parisi S; Simonetti G; Paolini S; Sartor C; Ottaviani E; Testoni N; Martinelli G
Expert Opin Pharmacother; 2016 Dec; 17(18):2479-2486. PubMed ID: 27829292
[TBL] [Abstract][Full Text] [Related]
43. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
[TBL] [Abstract][Full Text] [Related]
44. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
[TBL] [Abstract][Full Text] [Related]
45. Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine.
Li H; Wang Y; Pang X; Xie C; Deeg JH; Wang H; Wan T; Wu J; Guan F; Li X
Haematologica; 2020 Oct; 105(10):e502. PubMed ID: 33054092
[No Abstract] [Full Text] [Related]
46. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
[TBL] [Abstract][Full Text] [Related]
47. Epigenetic changes in the myelodysplastic syndrome.
Issa JP
Hematol Oncol Clin North Am; 2010 Apr; 24(2):317-30. PubMed ID: 20359628
[TBL] [Abstract][Full Text] [Related]
48. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
[TBL] [Abstract][Full Text] [Related]
49. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Zeidan AM; Salimi T; Epstein RS
Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
[TBL] [Abstract][Full Text] [Related]
50. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K
Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822
[TBL] [Abstract][Full Text] [Related]
51. DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.
Casellas Román HL; Venugopal K; Feng Y; Shabashvili DE; Posada LM; Li J; Guryanova OA
Leuk Res; 2020 Jul; 94():106372. PubMed ID: 32445940
[No Abstract] [Full Text] [Related]
52. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
Silverman LR
Leuk Res; 2009 Dec; 33 Suppl 2():S18-21. PubMed ID: 20004792
[TBL] [Abstract][Full Text] [Related]
53. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Link PA; Baer MR; James SR; Jones DA; Karpf AR
Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
[TBL] [Abstract][Full Text] [Related]
54. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
[TBL] [Abstract][Full Text] [Related]
55. Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool.
Kalinkova L; Sevcikova A; Stevurkova V; Fridrichova I; Ciernikova S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614080
[TBL] [Abstract][Full Text] [Related]
56. Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use.
Santini V; Ossenkoppele GJ
Crit Rev Oncol Hematol; 2019 Aug; 140():1-7. PubMed ID: 31153036
[TBL] [Abstract][Full Text] [Related]
57. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.
Campillo-Marcos I; Casado-Pelaez M; Davalos V; Ferrer G; Mata C; Mereu E; Roué G; Valcárcel D; Molero A; Zamora L; Xicoy B; Palomo L; Acha P; Manzanares A; Tobiasson M; Hellström-Lindberg E; Solé F; Esteller M
Cancer Res Commun; 2024 Feb; 4(2):365-377. PubMed ID: 38300528
[TBL] [Abstract][Full Text] [Related]
58. Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes.
Abbas HA; Reville PK; Jiang X; Yang H; Reuben A; Im JS; Little L; Sinson JC; Chen K; Futreal A; Garcia-Manero G
Front Immunol; 2021; 12():659625. PubMed ID: 33912187
[TBL] [Abstract][Full Text] [Related]
59. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Stein EM; Bonifacio G; Latremouille-Viau D; Shi S; Guerin A; Wu EQ; Sadek I; Cao X
Leuk Lymphoma; 2021 Jun; 62(6):1411-1421. PubMed ID: 33430673
[TBL] [Abstract][Full Text] [Related]
60. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]